In Wednesday’s Wall Street session, Relay Therapeutics Inc (NASDAQ:RLAY) shares traded at $2.95, down -6.35% from the previous session.
RLAY stock price is now -1.67% away from the 50-day moving average and -42.60% away from the 200-day moving average. The market capitalization of the company currently stands at $505.76M.
With the price target of $4, Wells Fargo recently initiated with Equal Weight rating for Relay Therapeutics Inc (NASDAQ: RLAY). On September 10, 2024, Jefferies Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock increasing its target price from $10.60 to quote $16, while ‘Goldman’ rates the stock as ‘Buy’
In other news, Rahmer Peter, insider sold 10,739 shares of the company’s stock on Apr 30 ’25. The stock was sold for $32,217 at an average price of $3.00. Upon completion of the transaction, the insider now directly owns 390,081 shares in the company, valued at $1.15 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 28 ’25, Rahmer Peter sold 1,364 shares of the business’s stock. A total of $4,324 was realized by selling the stock at an average price of $3.17. This leaves the insider owning 400,820 shares of the company worth $1.18 million. A total of 24.59% of the company’s stock is owned by insiders.
During the past 12 months, Relay Therapeutics Inc has had a low of $1.77 and a high of $10.72. As of last week, the company has a debt-to-equity ratio of 0.07, a current ratio of 19.96, and a quick ratio of 19.96.
The net profit margin was -4341.53% and return on equity was -45.46% for RLAY. The company reported revenue of $7.68 million for the quarter, compared to $10.01 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -23.26 percent.
